Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 77Lymphoma 62Melanoma 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 42Leukemia 41Lymphoma, Non-Hodgkin 31Burkitt Lymphoma 30Multiple Myeloma 28Leukemia, Lymphocytic, Chronic, B-Cell 26Neuroblastoma 24Lymphoma, Follicular 23Neoplasm Metastasis 21Leukemia, Myeloid, Acute 19Sarcoma 18Lymphoma, Large-Cell, Immunoblastic 18Neoplasms, Plasma Cell 17Lymphoma, Mantle-Cell 17Skin Neoplasms 16Ovarian Neoplasms 14Kidney Neoplasms 14Neoplasms 13Hodgkin Disease 13Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, B-Cell 11Central Nervous System Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Large-Cell, Anaplastic 10

Interventions

siplizumab 1liposomal doxorubicin 1Vincristine 1Rituximab 1Prednisone 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Subcutaneous panniculitis-like T-cell lymphoma × Cyclophosphamide × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡